This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wustrow, T. P. U. Articles by Good, R. A. Search for Related Content PubMed PubMed Citation Articles by Wustrow, T. P. U. Articles by Good, R. A.

Prevention of Leukemia and the Increase of Plasma Levels of Lipid-bound Sialic Acid by Allogeneic Bone Marrow Transplantation in Mice¹

Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [T. P. U. W., N. K., C. C. S.], and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104 [R. A. G.]

AKR/J (hereafter called AK) mice treated by total-body irradiation plus syngeneic marrow transplantation developed a leukemia-lymphoma complex and concomitantly showed increased levels of lipid-bound sialic acid as was also seen in untreated AK mice between 6 weeks and 6 and 11.5 months of age.

C57BL/6J (hereafter called B6) mice did not show a leukemialymphoma complex and did not develop elevated levels of lipid-bound sialic acid with aging.

B6AK chimeras, prepared with B6 bone marrow deprived of Thy-1.2-positive cells prior to allogeneic transplantation and kept in laminar flow isolation, did not develop graft-versus-host reactions, lived long lives (observations carried up to 13 months), failed to develop leukemia-lymphoma, and had persistently low levels of lipid-bound sialic acid. These findings indicate that introduction of resistance by marrow transplantation can inhibit development of retrovirus-induced cancer and also prevents an increase in levels of a putative cancer indicator.

¹ This work was supported by USPHS Grants AI-19495 and AG-03592, American Cancer Society Research Grant 118, and the March of Dimes Birth Defects Foundation Grant 1-789.

² Recipient of the Deutsche Forschungsgemeinschaft Fellowship Grant WU-111/1.

³ Present address: Oklahoma Medical Research Foundation, 825 N.E. 13th St., Oklahoma City, OK 73104. To whom requests for reprints should be addressed.

Received 8/24/83. Accepted 11/ 6/84.